| ￥3000 | |
| Z05535-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 21.25 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of Interferon omega-1, His, Human is greater than 95% as determined by SEC-HPLC. »
Interferon omega-1, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
Human IFNAR1, His Tag immobilized on CM5 Chip can bind Interferon omega-1, His, Human, His Tag with an affinity constant of 20.96 μM as determined in SPR assay (Biacore T200). »
| Target Background | Human Interferon omega-1, a type I IFN, also known as IFN-ω1 or IFNW1, it contains a potential N-glycosylation site like human IFN-β. IFN-ω1 binds to the interferon alpha/beta receptor but not to the interferon gamma receptor. All IFN-ω genes analysed to date are devoid of introns. IFN-ω1 has been shown to be well-tolerated in man and to induce reductions of hepatitis C virus RNA levels in a series of human clinical trials. |
| Synonyms | Interferon alpha-II-1; IFNW1; IFN-ω1; IFN-omega-1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
